Hypoxia-mediated biological control

Journal of Cellular Biochemistry

Volumn 112, Issue 3, 2011, Pages 735-744

  Cassavaugh, Jessica ^a   Lounsbury, Karen M ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Angiogenesis; Cardiovascular preconditioning; HIF; Hypoxia

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; VASCULOTROPIN;

ANGIOGENESIS; AUTOPHAGY; BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CELL METABOLISM; CELL SURVIVAL; COLORECTAL CANCER; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; ENZYME REGULATION; GENE CONTROL; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HEART MUSCLE ISCHEMIA; HUMAN; HYDROXYLATION; HYPOXIA; ISCHEMIC HEART DISEASE; KIDNEY CANCER; LIVER CELL CARCINOMA; METASTASIS; NONHUMAN; OVARY CANCER; OXYGEN CONSUMPTION; OXYGEN SUPPLY; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; PROTEIN STABILITY; REVIEW; STOMACH CANCER; TISSUE SURVIVAL; UTERINE CERVIX CANCER;

ANOXIA; GENE EXPRESSION REGULATION; HUMANS; HYDROGEN-ION CONCENTRATION; HYPOXIA-INDUCIBLE FACTOR 1; MYOCARDIAL ISCHEMIA; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN;

EID: 79951807773     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22956     Document Type: Review

References (110)

1. Appelhoff RJ, Tian Y-M, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM. 2004. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279:38458-38465. (Pubitemid 39295997)
2. Baba M, Hirai S, Yamada-Okabe H, Hamada K, Tabuchi H, Kobayashi K, Kondo K, Yoshida M, Yamashita A, Kishida T, Nakaigawa N, Nagashima Y, Kubota Y, Yao M, Ohno S. 2003. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Oncogene 22:2728-2738. (Pubitemid 36609588)
3. Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS, Ogino S. 2010. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 176:2292-2301.
4. Bajpai J, Sharma M, Sreenivas V, Kumar R, Gamnagatti S, Khan S, Rastogi S, Malhotra A, Bakhshi S. 2009. VEGF expression as a prognostic marker in osteosarcoma. Pediatr Blood Cancer 53:1035-1039.
5. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruïne AP. 2010. VHL and HIF signalling in renal cell carcinogenesis. J Pathol 221:125-138.
6. Berta MA, Mazure N, Hattab M, Pouysségur J, Brahimi-Horn MC. 2007. SUMOylation of hypoxia-inducible factor-1alpha reduces its transcriptional activity. Biochem Biophys Res Commun 360:646-652. (Pubitemid 47048148)
7. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. 2000. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60:4693-4696.
8. Bristow RG, Hill RP. 2008. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8:180-192.
9. Cao D, Hou M, Guan YS, Jiang M, Yang Y, Gou HF. 2009. Expression of HIF-1alpha and VEGF in colorectal cancer: Association with clinical outcomes and prognostic implications. BMC Cancer 9:432.
10. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT. 1998. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 95:11715-11720. (Pubitemid 28460480)
11. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. 2001. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 276:9519-9525.
12. Chiche J, Brahimi-Horn MC, Pouysségur J. 2010. Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer. J Cell Mol Med 14:771-794.
13. Chung AS, Lee J, Ferrara N. 2010. Targeting the tumour vasculature: Insights from physiological angiogenesis. Nat Rev Cancer 10:505-514.
14. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH. 2000. Hypoxia inducible factoralpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275:25733-25741.
15. Delli Carpini J, Karam AK, Montgomery L. 2010. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 13:43-58.
16. Doege K, Heine S, Jensen I, Jelkmann W, Metzen E. 2005. Inhibition of mitochondrial respiration elevates oxygen concentration but leaves regulation of hypoxia-inducible factor (HIF) intact. Blood 106:2311-2317. (Pubitemid 41510801)
17. Dorevic G, Matusan-Ilijas K, Babarovic E, Hadzisejdic I, Grahovac M, Grahovac B, Jonjic N. 2009. Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. J Exp Clin Cancer Res 28:40.
18. Duan LJ, Zhang-Benoit Y, Fong GH. 2005. Endothelium-intrinsic requirement for Hif-2alpha during vascular development. Circulation 111:2227-2232. (Pubitemid 40632439)
19. Eckle T, Kohler D, Lehmann R, El Kasmi KC, Eltzschig HK. 2008. Hypoxia-inducible factor-1 is central to cardioprotection: A new paradigm for ischemic preconditioning. Circulation 118:166-175.
20. Elkins JM, Hewitson KS, McNeill LA, Seibel JF, Schlemminger I, Pugh CW, Ratcliffe PJ, Schofield CJ. 2003. Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1 alpha. J Biol Chem 278:1802-1806. (Pubitemid 36801416)
21. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54. (Pubitemid 32972036)
22. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med 9:669-676. (Pubitemid 36749215)
23. Finger E, Giaccia A. 2010. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 29:285-293.
24. Fong GH. 2008. Mechanisms of adaptive angiogenesis to tissue hypoxia. Angiogenesis 11:121-140.
25. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613. (Pubitemid 26272112)
26. Frantz S, Vincent KA, Feron O, Kelly RA. 2005. Innate immunity and angiogenesis. Circ Res 96:15-26. (Pubitemid 40095751)
27. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL. 2007. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129:111-122. (Pubitemid 46507584)
28. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, Lee LA, Semenza GL, Dang CV. 2007. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12:230-238. (Pubitemid 47333417)
29. Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, Pouyssegur J, Yaniv M, Mechta-Grigoriou F. 2004. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118:781-794. (Pubitemid 39221736)
30. Gerber H-P, Condorelli F, Park J, Ferrara N. 1997. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. J Biol Chem 272:23659-23667.
31. Gort EH, van Haaften G, Verlaan I, Groot AJ, Plasterk RH, Shvarts A, Suijkerbuijk KP, van Laar T, van der Wall E, Raman V, van Diest PJ, Tijsterman M, Vooijs M. 2008. The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2alpha. Oncogene 27:1501-1510. (Pubitemid 351347879)
32. Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA. 1998. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 7:205-213. (Pubitemid 28527216)
33. Haase VH. 2010. Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol 299:F1-F13.
34. Hagen T, Taylor CT, Lam F, Moncada S. 2003. Redistribution of intracellular oxygen in hypoxia by nitric oxide: Effect on HIF1alpha. Science 302:1975-1978. (Pubitemid 37523507)
35. Hanze J, Weissmann N, Grimminger F, Seeger W, Rose F. 2007. Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling. Thromb Haemost 97:774-787. (Pubitemid 46779962)
36. Harris AL. 2002. Hypoxia - A key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47. (Pubitemid 37328806)
37. Hirsila M, Koivunen P, Gunzler V, Kivirikko KI, Myllyharju J. 2003. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 278:30772-30780. (Pubitemid 36994584)
38. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. 2003. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23:9361-9374. (Pubitemid 37499822)
39. Huang ST, Vo KC, Lyell DJ, Faessen GH, Tulac S, Tibshirani R, Giaccia AJ, Giudice LC. 2004. Developmental response to hypoxia. FASEB J 18:1348-1365. (Pubitemid 39150350)
40. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT. 2002. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004-7014.
41. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, Gatter KC, Johnson PJ, Harris AL. 2002. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8:2595-2604. (Pubitemid 34856346)
42. Hyvarinen J, Hassinen IE, Sormunen R, Maki JM, Kivirikko KI, Koivunen P, Myllyharju J. 2010. Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury. J Biol Chem 285:13646-13657.
43. Imai T, Horiuchi A, Wang C, Oka K, Ohira S, Nikaido T, Konishi I. 2003. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 163:1437-1447. (Pubitemid 37175091)
44. Irie N, Matsuo T, Nagata I. 2004. Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathol 21:1-6. (Pubitemid 38915175)
45. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ, Kim KW. 2002. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111:709-720. (Pubitemid 35441252)
46. Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, Campochiaro PA, Semenza GL. 2003. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 93:1074-1081. (Pubitemid 37485038)
47. Kido M, Du L, Sullivan C, Li X, Deutsch R, Jamieson SW, Thistlethwaite PA. 2005. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol 46:2116-2124. (Pubitemid 41713601)
48. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. 2006. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3:177-185.
49. Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, Baek JH, Semenza GL. 2006. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 66: 2725-2731.
50. Lahiri S, Roy A, Baby SM, Hoshi T, Semenza GL, Prabhakar NR. 2006. Oxygen sensing in the body. Prog Biophys Mol Biol 91:249-286.
51. Lawrentschuk N, Lee F, Jones G, Rigopoulos A, Mountain A, O'Keefe G, Papenfuss A, Bolton D, Davis I, Scott A. 2009. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and 124I-cG250 PET/CT. Urol Oncol [Epub ahead of print].
52. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. 2000. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 342:626-633. (Pubitemid 30118415)
53. Levy NS, Chung S, Furneaux H, Levy AP. 1998. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 273:6417-6423. (Pubitemid 28144735)
54. Li F, Sonveaux P, Rabbani ZN, Liu S, Yan B, Huang Q, Vujaskovic Z, Dewhirst MW, Li CY. 2007. Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 26:63-74. (Pubitemid 46550936)
55. Liao D, Corle C, Seagroves TN, Johnson RS. 2007. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 67:563-572. (Pubitemid 46192193)
56. Lisy K, Peet DJ. 2008. Turn me on: Regulating HIF transcriptional activity. Cell Death Differ 15:642-649. (Pubitemid 351405067)
57. Lounsbury KM, Hu Q, Ziegelstein RC. 2000. Calcium signaling and oxidant stress in the vasculature. Free Radic Biol Med 28:1362-1369. (Pubitemid 30621480)
58. Lyng H, Sundfor K, Trope C, Rofstad EK. 2000. Disease control of uterine cervical cancer: Relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy. Clin Cancer Res 6:1104-1112. (Pubitemid 30159373)
59. Mahon PC, Hirota K, Semenza GL. 2001. FIH-1: A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15:2675-2686. (Pubitemid 32988878)
60. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, Cao Y, Berkenstam A, Poellinger L. 2001. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414: 550-554. (Pubitemid 33131538)
61. Maxwell PH, Pugh CW, Ratcliffe PJ. 1993. Inducible operation of the erythropoietin 30 enhancer in multiple cell lines: Evidence for a wide-spread oxygen-sensing mechanism. Proc Natl Acad Sci USA 90:2423-2427. (Pubitemid 23078639)
62. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275. (Pubitemid 29246458)
63. Maynard MA, Evans AJ, Hosomi T, Hara S, Jewett MA, Ohh M. 2005. Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma. FASEB J 19:1396-1406. (Pubitemid 41278998)
64. Mole DR, Ratcliffe PJ. 2008. Cellular oxygen sensing in health and disease. Pediatr Nephrol 23:681-694. (Pubitemid 351486180)
65. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. 2002. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160:985-1000. (Pubitemid 34224587)
66. Mukhopadhyay CK, Mazumder B, Fox PL. 2000. Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem 275:21048-21054. (Pubitemid 30481794)
67. Mylonis I, Chachami G, Samiotaki M, Panayotou G, Paraskeva E, Kalousi A, Georgatsou E, Bonanou S, Simos G. 2006. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem 281:33095-33106. (Pubitemid 46043259)
68. Nam DH, Park K, Suh YL, Kim JH. 2004. Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: Prognostic significance. Oncol Rep 11:863-869.
69. Osada R, Horiuchi A, Kikuchi N, Yoshida J, Hayashi A, Ota M, Katsuyama Y, Melillo G, Konishi I. 2007. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: Nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 38:1310-1320. (Pubitemid 47247486)
70. Pan Y, Mansfield KD, Bertozzi CC, Rudenko V, Chan DA, Giaccia AJ, Simon MC. 2007. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol 27:912-925. (Pubitemid 46174556)
71. Pepper MS, Ferrara N, Orci L, Montesano R. 1991. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 181:902-906.
72. Peyssonnaux C, Nizet V, Johnson RS. 2008. Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle 7:28-32.
73. Qiu MZ, Han B, Luo HY, Zhou ZW, Wang ZQ, Wang FH, Li YH, Xu RH. 2010. Expressions of hypoxia-inducible factor-1alpha and hexokinase-II in gastric adenocarcinoma: The impact on prognosis and correlation to clinicopathologic features. Tumour Biol 32(1):159-166.
74. Rane S, He M, Sayed D, Vashistha H, Malhotra A, Sadoshima J, Vatner DE, Vatner SF, Abdellatif M. 2009. Downregulation of MiR-199a derepresses hypoxia-inducible factor-1{alpha} and sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 104:879-886.
75. Rankin EB, Giaccia AJ. 2008. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15:678-685. (Pubitemid 351405072)
76. Rolfe DF, Brown GC. 1997. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol Rev 77:731-758. (Pubitemid 27328739)
77. Ryan HE, Lo J, Johnson RS. 1998. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17:3005-3015. (Pubitemid 28254373)
78. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. 2009. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: Systematic review and meta-analysis. Br J Cancer 100:1385-1392.
79. Scortegagna M, Ding K, Oktay Y, Gaur A, Thurmond F, Yan LJ, Marck BT, Matsumoto AM, Shelton JM, Richardson JA, Bennett MJ, Garcia JA. 2003. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat Genet 35:331-340. (Pubitemid 37486916)
80. Seagroves TN, Ryan HE, Lu H, Wouters BG, Knapp M, Thibault P, Laderoute K, Johnson RS. 2001. Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol Cell Biol 21:3436-3444. (Pubitemid 32381779)
81. Semenza GL. 2001. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 13:167-171. (Pubitemid 32209217)
82. Semenza GL. 2003. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732. (Pubitemid 37328811)
83. Semenza GL. 2010. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625-634.
84. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. 1991. Hypoxia-inducible nuclear factors bind to an enhancer element located 30 to the human erythropoietin gene. Proc Natl Acad Sci USA 88:5680-5684. (Pubitemid 21914809)
85. Semenza GL, Wang GL. 1992. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12:5447-5454.
86. Shen B-Q, Lee DY, Gerber H-P, Keyt BA, Ferrara N, Zioncheck TF. 1998. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem 273:29979-29985. (Pubitemid 28510016)
87. Shimoda LA, Fallon M, Pisarcik S, Wang J, Semenza GL. 2006. HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol 291:L941-L949.
88. Simon MC, Keith B. 2008. The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol 9:285-296.
89. Simons M. 2005. Angiogenesis: Where do we stand now? Circulation 111:1556-1566.
90. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI. 2002. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95:1055-1063.
91. Stubbs M, Griffiths JR. 2010. The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. Adv Enzyme Regul 50:44-55.
92. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. 2000. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157:411-421.
93. Taylor CT. 2008. Mitochondria and cellular oxygen sensing in the HIF pathway. Biochem J 409:19-26.
94. Teicher BA. 2010. Antiangiogenic agents and targets: A perspective. Biochem Pharmacol 81(1):6-12.
95. Theodoropoulos VE, Lazaris A, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I, Manikas K, Kastriotis I. 2004. Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 46:200-208.
96. Tian H, McKnight SL, Russell DW. 1997. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11:72-82.
97. Tongers J, Roncalli JG, Losordo DW. 2008. Therapeutic angiogenesis for critical limb ischemia: Microvascular therapies coming of age. Circulation 118:9-16.
98. Ullah MS, Davies AJ, Halestrap AP. 2006. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha dependent mechanism. J Biol Chem 281:9030-9037.
99. Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324:1029-1033.
100. Vaupel P, Briest S, Hockel M. 2002. Hypoxia in breast cancer: Pathogenesis, characterization and biological/therapeutic implications. Wien Med Wochenschr 152:334-342.
101. 2 tension. Proc Natl Acad Sci USA 92:5510-5514.
102. Wang V, Davis DA, Haque M, Huang LE, Yarchoan R. 2005. Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Res 65:3299-3306.
103. Wellman TL, Jenkins J, Penar PL, Tranmer B, Zahr R, Lounsbury KM. 2004. Nitric oxide and reactive oxygen species exert opposing effects on the stability of hypoxia-inducible factor-1alpha (HIF-1alpha) in explants of human pial arteries. FASEB J 18:379-381.
104. Wiesener MS, Jurgensen JS, Rosenberger C, Scholze C, Horstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, Eckardt K-U. 2002. Widespread, hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 17(2):271-273.
105. Wong C, Wellman TL, Lounsbury KM. 2003. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol 91:513-517.
106. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. 2000. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60:7075-7083.
107. Xue W, Cai L, Tan Y, Thistlethwaite P, Kang YJ, Li X, Feng W. 2010. Cardiac-specific overexpression of HIF-1alpha prevents deterioration of glycolytic pathway and cardiac remodeling in streptozotocin-induced diabetic mice. Am J Pathol 177:97-105.
108. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ. 2008. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10:295-305.
109. Yang QC, Zeng BF, Dong Y, Shi ZM, Jiang ZM, Huang J. 2007. Over-expression of hypoxia-inducible factor-1alpha in human osteosarcoma: Correlation with clinicopathological parameters and survival outcome. Jpn J Clin Oncol 37:127-134.
110. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB, Gonzalez FJ, Semenza GL. 2008. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 283:10892-10903.